Skip to main content

Advertisement

SpringerLink
Log in

Depression During Pregnancy and Postpartum

  • Complex Medical-Psychiatric Issues (MB Riba, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Depression is a common complication of pregnancy and the postpartum period. There are multiple risk factors for peripartum mood disorders, most important of which is a prior history of depression. Both depression and antidepressant medications confer risk upon the infant. Maternal depression has been associated with preterm birth, low birth weight, fetal growth restriction, and postnatal cognitive and emotional complications. Antidepressant exposure has been associated with preterm birth, reductions in birth weight, persistent pulmonary hypertension, and postnatal adaptation syndrome (PNAS) as well as a possible connection with autism spectrum disorder. Paroxetine has been associated with cardiac malformations. Most antidepressant medications are excreted in low levels in breast milk and are generally compatible with breastfeeding. The use of antidepressants during pregnancy and postpartum must be weighed against the risk of untreated depression in the mother.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of Importance •• Of Major importance

  1. Committee on Obstetric Practice. The American College of Obstetricians and Gynecologists Committee Opinion no. 630. Screening for perinatal depression. Obstet Gynecol. 2015;125(5):1268–71.

    Article  Google Scholar 

  2. ACOG Committee. Clinical Management Guidelines for Obstetrician–Gynecologists: use of psychiatric medications during pregnancy and lactation. ACOG Practice Bulletin No. 92. Obstet Gynecol. 2008;111(4):1001–20.

    Article  Google Scholar 

  3. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31(5):403–13.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Wisner KL, Sit DK, McShea MC, Rizzo DM, Zoretich RA, Hughes CL, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013;70(5):490–8. doi:10.1001/jamapsychiatry.2013.87.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. 2005;8(2):77–87.

  6. Raisanen S, Lehto SM, et al. Risk factors for perinatal outcomes of major depression during pregnancy: a population-based analysis during 2002-2010 in Finland. BMJ Open. 2014;4(11):e004883.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy and in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.

    Article  CAS  PubMed  Google Scholar 

  8. Szegda K, Markenson G, Bertone-Johnson ER, Chasan-Taber L. Depression during pregnancy: a risk factor for adverse neonatal outcomes? A critical review of the literature. J Matern Fetal Neonatal Med. 2014;27(9):960–7.

    Article  PubMed  Google Scholar 

  9. Grigoriadis S, VonderPorten EH, Mamisahvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e321–41.

    Article  PubMed  Google Scholar 

  10. Ciesielski TH, Marsit CJ, Williams SM. Maternal psychiatric disease and epigenetic evidence suggest a common biology for poor fetal growth. BMC Pregnancy Childbirth. 2015;15:192. doi:10.1186/s12884-015-0627-8.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Davalos DB, Yadon CA, Tregellas HC. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health. 2012;15(1):1–14. doi:10.1007/s00737-011-0251-1.

    Article  PubMed  Google Scholar 

  12. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10):1012–24.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Iliadis SI, Comasco E, Sylvén S, Hellgren C, Sundström Poromaa I, Skalkidou A. Prenatal and postpartum evening salivary cortisol levels in association with peripartum depressive symptoms. PLoS One. 2015;10(8):e0135471. doi:10.1371/journal.pone.0135471.eCollection2015.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Federenko IS, Wadhwa PD. Women’s mental health during pregnancy influences fetal and infant developmental and health outcomes. CNS Spectr. 2004;9(3):198–206.

    PubMed  Google Scholar 

  15. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics. 2008;3:97–106.

    Article  PubMed  Google Scholar 

  16. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557–66. doi:10.1176/appi.ajp.2008.08081170.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Pearson RM, Melotti R, Heron J, Joinson C, Stein A, Ramchandani PG, et al. Disruption to the development of maternal responsiveness? The impact of prenatal depression on mother-infant interactions. Infant Behav Dev. 2012;35(4):613–26. doi:10.1016/j.infbeh.2012.07.020.

    Article  CAS  PubMed  Google Scholar 

  18. Robertson E, Grace S, Wallington T, et al. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. 2004;26:289–95.

    Article  PubMed  Google Scholar 

  19. Beck CT. Predictors of postpartum depression: an update. Nurs Res. 2001;50(5):275–85.

    Article  CAS  PubMed  Google Scholar 

  20. Gaillard A, Le Strat Y, Mandelbrot L, et al. Predictors of postpartum depression: prospective study of 264 women followed during pregnancy and postpartum. Psychiatry Res. 2014;215(2):341–6.

    Article  PubMed  Google Scholar 

  21. Kimmel M, Hess E, Roy PS. Family history, not lack of medication use, is associated with the development of postpartum depression in a high-risk sample. Arch Womens Ment Health. 2015;18:113–21.

    Article  PubMed  Google Scholar 

  22. Bloch M, Rotenberg N, Koren D, Klein E. Risk factors associated with the development of postpartum mood disorders. J Affect Disord. 2005;88(1):9–18.

    Article  PubMed  Google Scholar 

  23. Davanzo R, Copertino M, DeCunto A, et al. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med. 2011;6(2):89–98.

    Article  PubMed  Google Scholar 

  24. Dubber S, Reck C, Müller M, Gawlik S. Postpartum bonding: the role of perinatal depression, anxiety and maternal-fetal bonding during pregnancy. Arch Womens Ment Health. 2015;18(2):187–95. doi:10.1007/s00737-014-0445-4.

    Article  CAS  PubMed  Google Scholar 

  25. McLearn KT, Minkovitz CS, Strobino DM, Marks E, Hou W. Maternal depressive symptoms at 2 to 4 months post partum and early parenting practices. Arch Pediatr Adolesc Med. 2006;160(3):279–84.

    Article  PubMed  Google Scholar 

  26. Paulson JF, Dauber S, Leiferman JA. Individual and combined effects of postpartum depression in mothers and fathers on parenting behavior. Pediatrics. 2006;118(2):659–68.

    Article  PubMed  Google Scholar 

  27. Dias CC, Figueiredo B. Breastfeeding and depression: a systematic review of the literature. J Affect Disord. 2015;171:142–54. doi:10.1016/j.jad.2014.09.022.

    Article  PubMed  Google Scholar 

  28. Hatton DC, Harrison–Hohner J, Coste S, et al. Symptoms of postpartum depression and breastfeeding. J Hum Lac. 2005;21(44):444–9.

    Article  Google Scholar 

  29. Feldman R, Granat A, Pariente C, et al. Maternal depression and anxiety across the postpartum year and infant social engagement, fear regulation, and stress reactivity. J Am Acad Child Adolesc Psychiatry. 2009;48(9):919–27.

    Article  PubMed  Google Scholar 

  30. Grace SL, Evindar A, Stewart DE. The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. Arch Women s Mental Health. 2003;6:263–74.

    Article  CAS  Google Scholar 

  31. Pilowsky DJ, Wickramaratne PJ, Rush AJ, Hughes CW, Garber J, Malloy E, et al. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry. 2006;67(1):126–36.

    Article  PubMed  Google Scholar 

  32. Biederman J, Faraone SV, Hirshfel-Becker DR, Friedman D, Robin JA, Rosenbaum JF. Patterns of psychopathology and dysfunction in high-risk children of parents with panic disorder and major depression. Am J Psychiatry. 2001;158(1):59–7.

    Article  Google Scholar 

  33. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7:28–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Fihrer I, McMahon CA, Taylor AJ. The impact of postnatal and concurrent maternal depression on child behavior during the early school years. J Affect Disord. 2009;119:116–23.

    Article  PubMed  Google Scholar 

  35. Werner E, Miller M, Osborne LM, Kuzava S, Monk C. Preventing postpartum depression: review and recommendations. Arch Womens Ment Health. 2015;18(1):41–60.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Sokol LE, Epperson CN, Barber JP. Preventing postpartum depression: a meta-analytic review. Clin Psychol Rev. 2013;33(8):1205–17.

    Article  Google Scholar 

  37. USPTF. Final recommendation statement; depression in adults: screening. J Am Med Assoc. 2016;315(4):380–7

  38. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2012:1–21. This is a large critical, comprehensive review examining multiple outcomes on teratogenicity, postnatal adaptation syndrome, and persistent pulmonary hypertension.

  39. Suri R, Lin AS, et al. Acute and long-term behavioral outcomes of infants and children exposed in utero to either maternal depression or antidepressants: a review of the literature. J Clin Psychiatr. 2014;75(10):e1142–52.

    Article  Google Scholar 

  40. Grigoriadis S. The effects of antidepressant medications on mothers and babies. J Popul Ther Clin Pharmacol. 2014;21(3):e533–41.

    PubMed  Google Scholar 

  41. Drug labelling and pregnancy. Lancet. 2014 Dec 13;384(9960):2084. doi: 10.1016/S0140-6736(14)62356-4.

  42. Ramoz LL, Patel Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy. 2014;34(4):389–95.

    Article  PubMed  Google Scholar 

  43. Food and Drug Administration, HHS. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014;79(233).

  44. Louik C, Lin A, Werler M, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675–83.

    Article  CAS  PubMed  Google Scholar 

  45. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systemic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74(4):e293–308.

    Article  CAS  PubMed  Google Scholar 

  46. Kallen BA, Otterblad OP. Maternal use of selective serotonin-reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79(4):301–8.

    Article  PubMed  CAS  Google Scholar 

  47. Greene MF. Teratogenicity of SSRIs—serious concern or much ado about little? N Engl J Med. 2007;356:2732.

    Article  CAS  PubMed  Google Scholar 

  48. Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clinc Psychol. 2014;10:369–92.

    Article  Google Scholar 

  49. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:1798. 1-9.

  50. Alwan S, Reefhuis J, Rasmussen SA, for National Birth Defects Prevention Study, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684–92.

    Article  CAS  PubMed  Google Scholar 

  51. Kendall-Tackett K, Hale TW. The use of antidepressants in pregnant and breastfeeding women: a review of recent studies. J Hum Lact. 2010;26(2):187–95.

    Article  PubMed  Google Scholar 

  52. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88(3):159–70.

    Article  CAS  PubMed  Google Scholar 

  53. Bakker MK, Kerstjens-Fredierikse WS, Buys CH, et al. First trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88(2):94–100.

    CAS  PubMed  Google Scholar 

  54. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(10):1075–85.

    Article  PubMed  Google Scholar 

  55. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723–33.

    Article  CAS  PubMed  Google Scholar 

  56. Tuccori M. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressant sure pregnancy: a review. Clin Ther. 2009;31:1426–53.

    Article  CAS  PubMed  Google Scholar 

  57. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with the use of paroxetine during pregnancy. Am J Psychiatry. 2008;165(6):749–52.

    Article  PubMed  Google Scholar 

  58. Davis RL, Rubanowice D, McPhillips H, et al. Risk of congenital malformations and perinatal events among infants exposed to antidepressant medication during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):186–94.

    Article  Google Scholar 

  59. Huybrechts KF, Palmesten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–407. This was a large cohort study with 949,504 pregnant women comparing those who took antidepressants to those who did not, which found no substantial increase in the risk of cardiac malformations attributable to antidepressant use during the first trimester.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183–92.

    Article  PubMed  Google Scholar 

  61. Gentile S. Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms. Expert Opin Drug Metab Toxicol. 2015;1:1–13.

    Google Scholar 

  62. Huybrechts KF, Snghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One. 2014;9(3):e92778.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  63. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192:338–43.

    Article  PubMed  Google Scholar 

  64. Suri R, Alshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatr. 2007;164(8):1206–13.

    Article  PubMed  Google Scholar 

  65. Ross LE, Grigoriadis S, Mamisashvili L, VonderPorten EH, Roerecke M, Rehm J, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70:436–43. A review article looking at selected outcomes after exposure to antidepressant medications; this study showed that there was no association between antidepressant exposures. It also showed that there was an association with low birth weight, but compared to depressed moms without exposure, this was no longer a significant association. There have been adverse outcomes associated with both antidepressant exposure and depression.

    Article  PubMed  Google Scholar 

  66. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36(1):13–8.

    Article  CAS  PubMed  Google Scholar 

  67. Sahingoz M, Yuksel G, Karsidag C, Uguz F, Sonmez EO, Annagur BB, et al. Birth weight and preterm birth in babies of pregnant women with major depression in relation to treatment with antidepressants. J Clin Psychopharmacol. 2014;34(2):226–9.

    Article  PubMed  CAS  Google Scholar 

  68. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Manusson C. Parental depression, maternal antidepressant use during pregnancy, and the risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.

    Article  PubMed Central  PubMed  Google Scholar 

  69. El Marroun H, Whilte T, Verhulst FC, Tiemeier H. Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review. Eur Child Adolesc Psychiatry. 2014;23(10):973–92.

    Article  PubMed  Google Scholar 

  70. Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014;133(5):e1241–8.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104–12.

    Article  PubMed  Google Scholar 

  72. Sorensen MJ, Gronborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol. 2013;5:449–59.

    Article  PubMed Central  PubMed  Google Scholar 

  73. Kallen Bm KOlausson PO. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidmiol Drug Saf. 2008;17:801–6.

    Article  Google Scholar 

  74. Huybrecs KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and the risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51.

    Article  CAS  Google Scholar 

  75. Kieler H, Artama M, Anders Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344. doi: 10.1136/bmj.d8012 (Published 12 January 2012) Cite this as: BMJ 2012;344:d8012

  76. Chambers CD et al. Selective serotonin reuptake inhibitors and the risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–87.

    Article  CAS  PubMed  Google Scholar 

  77. Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med. 2002;139:194–201.

    Article  CAS  PubMed  Google Scholar 

  78. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18:246–52.

    Article  PubMed  Google Scholar 

  79. Administration USFAD. FDA drug safety communication: selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 12/4/11 ed2011.

  80. Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;14:348.

    Google Scholar 

  81. Byatt N, Freeman MP. Exposure to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low. Evid Based Nurs. 2015;18(1):15–6.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Chambers CD, Johnson KA, Dick LM, Feliz RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010–5.

    Article  CAS  PubMed  Google Scholar 

  83. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–83.

    Article  CAS  PubMed  Google Scholar 

  84. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607–13.

    Article  PubMed  Google Scholar 

  85. Hibbard JU, Wilkins I, Sun L, et al. Respiratory morbidity in late preterm births. JAMA. 2010;304:419–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Byatt N et al. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013;127:94–114.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Canadian Journal of Psychiatry (Revue Canadienne de Psychiatrie). 2003;48(2):106–10.

    Google Scholar 

  88. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective studies. Pharmacoepidemiol Drug Saf. 2005;14(12):823–7.

    Article  CAS  PubMed  Google Scholar 

  89. Winterfeld U et al. Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. J Clin Psychopharmacol. 2015;35(3):250–9.

    Article  CAS  PubMed  Google Scholar 

  90. Djulus J et al. Exposure to mirtazapine during pregnancy: a prospective and comparative study of birth outcomes. J Clin Psych. 2006;67(8):1280–4.

    Article  CAS  Google Scholar 

  91. GlaxoSmithKline. The Bupropion Pregnancy Registry final report. (2008): http://pregnnacy-registry.gsk.com/documents/bup_report_final-2008.pdf.

  92. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203(1):52.e1–6.

    Article  CAS  Google Scholar 

  93. Chun-Fai-Chan B, Koren G, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932–6.

    Article  CAS  PubMed  Google Scholar 

  94. Howard LM, Molyneux E, Dennis CL, Tamsen R, Stein A, Milgrom J. Non-psychotic mental disorders in the perinatal period. Perinatal Mental Health The Lancet. 2014;384(9956):15–21.

    Google Scholar 

  95. Anderson PO, Pochop SL, Manoguerra AS. Adverse drug reactions in breastfed infants: less than imagined. Clin Pediatr. 2003;42:325–40.

    Article  Google Scholar 

  96. Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs. 2006;20(3):187–98.

    Article  CAS  PubMed  Google Scholar 

  97. Lanza DiScalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009;52(3):483–97.

    Article  Google Scholar 

  98. Lester BM, Cucca J, Andreozzi L, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993;32:1253–5.

    Article  CAS  PubMed  Google Scholar 

  99. Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999;48(4):521–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  100. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161:1066–78.

    Article  PubMed  Google Scholar 

  101. Field T. Breastfeeding and antidepressants. Infant Behav Dev. 2008;31(3):481–7.

    Article  PubMed Central  PubMed  Google Scholar 

  102. Gentile S. Use of contemporary antidepressants during breastfeeding: a proposal for a specific safety index. Drug Saf. 2007;30(2):107–21.

    Article  CAS  PubMed  Google Scholar 

  103. Potts AL, Young KL, Carter BS, Shenai JP. Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. J Perinatol. 2007;27:120–2.

    Article  CAS  PubMed  Google Scholar 

  104. Chad L, Pupco A, Bozzo P, Koren G. Update on antidepressant use during breastfeeding. Can Fam Physician. 2013;59:633–4.

    PubMed Central  PubMed  Google Scholar 

  105. Andrade C. The safety of duloxetine during pregnancy and lactation. J Clin Psychiatry. 2014;75(12):e1423–7.

    Article  PubMed  Google Scholar 

  106. Rampono J, Teoh S, Hackett LP et al. Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression. Arch Womens Ment Health. 2011;14:49–53.

  107. Baab SW, Peindl KS, Piontek CW, Wisner KL. Serum bupropion levels in 2 breastfeeding mother-infant pairs. J Clin Psychiatry. 2002;63(10):910–1.

    Article  PubMed  Google Scholar 

  108. Haas J, Kaplan C, Barenboim D, et al. Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control. 2004;13(1):52–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  109. Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of a possible infant seizure. J Clin Psychiatry. 2004;65(6):881–2.

    Article  PubMed  Google Scholar 

  110. Aichhorn W, Whitworth AB, Weiss U, Stuppaeck C. Letters to the editor: Mirtazapine and breastfeeding. Am J Psychiatry. 2004;161(12):2325.

    Article  PubMed  Google Scholar 

  111. Klier CM, Moussaheb N, Lee A, Zernig G. Letters to the editor: Mirtazapine and breastfeeding: maternal and infant plasma levels. Am J Psychiatry. 2007;164(2):348–9.

    Article  PubMed  Google Scholar 

  112. Kristensen JH, Ilett KF, Rampono J, et al. Transfer of the antidepressant mirtazapine into breast milk. Br J Clin Psychiatr. 2007;63(3):322–7.

    CAS  Google Scholar 

  113. Tonn P, Reuter SC, Hiemke C, Dahmen N. High mirtazapine plasma levels in infant after breast feeding: case report and review of the literature. J Clin Psychopharmacol. 2009;29(2):191–2.

    Article  PubMed  Google Scholar 

  114. Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol. 1986;22(3):367–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  115. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systemic review. Hum Psychopharmacol Clin Exp. 2015;30:4–20.

    Article  CAS  Google Scholar 

  116. Burt VK, Suri R, Altshuler L, et al. The use of psychotropic medications during breastfeeding. Am J Psychiatry. 2001;158:1001–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Human Behavior, Thomas Jefferson University Hospital, 1020 Sansom Street, Thompson Bldg, Suite 1652, Philadelphia, PA, 19107, USA

    Madeleine Becker, Ann Chandy & Sarah Schmukler

  2. Department of Psychiatry and Human Behavior, Thomas Jefferson University Hospital, 833 Chestnut St. 2nd floor, Suite 210, Philadelphia, PA, 19107, USA

    Tal Weinberger

Authors
  1. Madeleine Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tal Weinberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ann Chandy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah Schmukler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Madeleine Becker.

Ethics declarations

Conflict of Interest

Madeleine Becker, Tal Weinberger, Ann Chandy, and Sarah Schmukler declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Complex Medical-Psychiatric Issues

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Becker, M., Weinberger, T., Chandy, A. et al. Depression During Pregnancy and Postpartum. Curr Psychiatry Rep 18, 32 (2016). https://doi.org/10.1007/s11920-016-0664-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-016-0664-7

Keywords

Search

Navigation